ABCL Stock Overview
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AbCellera Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.77 |
| 52 Week High | US$14.97 |
| 52 Week Low | US$4.75 |
| Beta | 0.012 |
| 1 Month Change | -13.43% |
| 3 Month Change | -24.88% |
| 1 Year Change | -48.26% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.90% |
Recent News & Updates
Recent updates
Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?
Feb 04
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate
Nov 29AbCellera Biologics: Many Reasons To Own This Undervalued Stock
Sep 06AbCellera Biologics: COVID Antibody Set To Provide Continued Funding
Aug 14AbCellera partnering with Atlas Ventures on development of therapeutic antibodies
Aug 03AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying
Jun 06Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)
May 13Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%
May 07AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment
Apr 22AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm
Feb 11AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues
Dec 05AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy
Oct 18AbCellera Biologics: I Was Wrong
Aug 20AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be
Aug 17AbCellera Biologics: A Buy At Current Prices
Aug 06AbCellera Biologics: My Highest Conviction Pick, With The Longest Potential Payoff
May 31Analysts Just Slashed Their AbCellera Biologics Inc. (NASDAQ:ABCL) EPS Numbers
May 16Lilly-AbCellera collaboration develops new antibody that can neutralize COVID-19 variants
May 04We Think That There Are Issues Underlying AbCellera Biologics' (NASDAQ:ABCL) Earnings
Apr 06Time To Worry? Analysts Are Downgrading Their AbCellera Biologics Inc. (NASDAQ:ABCL) Outlook
Apr 01What You Need To Know About AbCellera Biologics Inc.'s (NASDAQ:ABCL) Investor Composition
Mar 13Shareholder Returns
| ABCL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -7.0% | -2.0% | -2.7% |
| 1Y | -48.3% | -1.0% | 16.8% |
Return vs Industry: ABCL underperformed the US Life Sciences industry which returned -2.9% over the past year.
Return vs Market: ABCL underperformed the US Market which returned 15.1% over the past year.
Price Volatility
| ABCL volatility | |
|---|---|
| ABCL Average Weekly Movement | 8.0% |
| Life Sciences Industry Average Movement | 7.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: ABCL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ABCL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 590 | Carl Hansen | https://www.abcellera.com |
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners.
AbCellera Biologics Inc. Fundamentals Summary
| ABCL fundamental statistics | |
|---|---|
| Market Cap | US$1.38b |
| Earnings (TTM) | -US$73.91m |
| Revenue (TTM) | US$145.18m |
9.5x
P/S Ratio-18.7x
P/E RatioIs ABCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABCL income statement (TTM) | |
|---|---|
| Revenue | US$145.18m |
| Cost of Revenue | US$160.54m |
| Gross Profit | -US$15.36m |
| Other Expenses | US$58.55m |
| Earnings | -US$73.91m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | -10.58% |
| Net Profit Margin | -50.91% |
| Debt/Equity Ratio | 0% |
How did ABCL perform over the long term?
See historical performance and comparison